Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | PRKCA | P17252 | 5/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.74 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.74 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9010956 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL10620809 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL8467738 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL7416016 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL16726792 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL3763399 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL9070261 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL9787451 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL10893167 | 1.00 | MAPT (0.75) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL14952939 | 0.94 | PRKCA (0.67) | MAPTMAPK1PRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9084821-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130251763-A1 | TRANSDERMAL COMPOSITIONS | MICRODERMIS CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-8536228-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2013-09-17 | — | — | US | disclosed |
| US-20120022165-A1 | TRANSDERMAL COMPOSITIONS | MICRODERMIS CORPORATION (US) | 2012-01-26 | — | — | US | disclosed |
| US-8101163-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2012-01-24 | — | — | US | disclosed |
| US-7893285-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2011-02-22 | — | — | US | disclosed |
| US-7888393-B2 | Transdermal compositions | MICRODERMIS CORPORATION (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100227929-A1 | TRANSDERMAL COMPOSITIONS | DRS. SOLUTIONS, LLC (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100203005-A1 | TRANSDERMAL COMPOSITIONS | DRS. SOLUTIONS, LLC (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100197795-A1 | TRANSDERMAL COMPOSITIONS | DRS. SOLUTIONS, LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-20040122105-A1 | Transdermal compositions | DRSS GLOBAL, LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004026259-A2 | TRANSDERMAL COMPOSITIONS | BETTLE GRISCOM III (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130251763-A1 | TRANSDERMAL COMPOSITIONS | S100A10, TMSB10, FFAR3 | MAPT 2191/4885MAPK1 3616/4885PRKCA 2017/4885 |
| US-20100203005-A1 | TRANSDERMAL COMPOSITIONS | S100A10, TMSB10, FFAR3 | MAPT 2191/4885MAPK1 3616/4885PRKCA 2017/4885 |
| US-20100197795-A1 | TRANSDERMAL COMPOSITIONS | S100A10, TMSB10, DGKG | MAPT 2137/4885MAPK1 3704/4885PRKCA 1981/4885 |
| US-20120022165-A1 | TRANSDERMAL COMPOSITIONS | S100A10, TMSB10, FFAR3 | MAPT 2191/4885MAPK1 3616/4885PRKCA 2017/4885 |
| US-20100227929-A1 | TRANSDERMAL COMPOSITIONS | S100A10, TMSB10, FFAR3 | MAPT 2191/4885MAPK1 3616/4885PRKCA 2017/4885 |
| US-20040122105-A1 | Transdermal compositions | S100A10, DGKG, COX6C | MAPT 2536/4885MAPK1 3538/4885PRKCA 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.